Back to Journals » Clinical Pharmacology: Advances and Applications » Volume 12

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]

Authors Hendrikx JJMA, Beijnen JH, Huitema ADR

Received 19 September 2020

Accepted for publication 3 October 2020

Published 30 October 2020 Volume 2020:12 Pages 177—178


Checked for plagiarism Yes

Editor who approved publication: Professor Arthur Frankel

Jeroen JMA Hendrikx,1– 3 Jos H Beijnen,1 Alwin DR Huitema1– 3

1Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 2Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 3Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

Correspondence: Jeroen JMA Hendrikx
Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1006 BE, The Netherlands
Tel +31 205 127 948

With great interest we read the paper by Liao et al in which they compared a 2-weekly bodyweight-based (6 mg/kg) and fixed (480 mg) administration of panitumumab, a monoclonal antibody (Mab) binding the  EGFR receptor.1 The authors used a population pharmacokinetics model to simulate pharmacokinetics of 1200 virtual individuals for each strategy. The observed interpatient variability in mean simulated AUC (CVAUCmean) was compared and was 34% (fixed dosing) versus 29% (bodyweight- based dosing). Based on this, the authors concluded for panitumumab that “body weight-based approach is the recommended patient dosing strategy”. 
View the original paper by Liao and colleagues

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]